In spite of abundant evidence demonstrating that in type 2 diabetes early glycemic control is correlated with a reduction in long‐term complications,1 data from many health systems indicate that delay in initiation and/or intensification of insulin therapy remains systemic.2, 3. The gene discussed is INS; the disease is type 2 diabetes mellitus.